The FDA clearance of Akili’s EndeavorOTC marks a significant advancement in the treatment of ADHD. As the first over-the-counter digital therapeutic for ADHD, EndeavorOTC leverages innovative technology to offer an engaging and effective solution for adults with attention issues. The rigorous clinical studies supporting this clearance highlight the product’s efficacy and safety, making it a valuable addition to the ADHD treatment landscape. Akili’s commitment to combining fun with therapeutic efficacy sets a new standard in digital medicine, offering patients a novel approach to managing their condition.